SCHEMBL21709403

SCHEMBL21709403

c1ccc(-c2ccc(-c3nc(N(c4ccccc4-c4ccccc4)c4cccc5c4-c4ccccc4C54c5ccccc5-c5ccccc54)c4ccccc4n3)cc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 10/20 0.40
CYP1A2 P05177 9/20 0.40
CYP3A4 P08684 8/20 0.40
CYP2C19 P33261 6/20 0.40
TSHR P16473 6/20 0.40
CYP2C9 P11712 5/20 0.40
ALDH1A1 P00352 5/20 0.40
PDE5A O76074 3/20 0.40
LMNA P02545 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
GLA P06280 2/20 0.40
KDM4E B2RXH2 2/20 0.40
HPGD P15428 2/20 0.40
HIF1A Q16665 2/20 0.40
MAPT P10636 2/20 0.40
ACP1 P24666 1/20 0.40
RECQL P46063 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
CLK4 Q9HAZ1 6/20 0.38
HSD17B10 Q99714 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21709504 0.92 CYP2D6 (0.45) CYP2D6CYP1A2CYP3A4CYP2C19TSHR
SCHEMBL21709458 0.89 CYP2D6 (0.41) CYP2D6CYP1A2CYP3A4CYP2C19TSHR
SCHEMBL21709402 0.88 CYP2D6 (0.42) CYP2D6CYP1A2CYP3A4CYP2C19TSHR
SCHEMBL21709404 0.85 CYP2D6 (0.44) CYP2D6CYP1A2CYP3A4CYP2C19TSHR
SCHEMBL21709502 0.82 CYP1A2 (0.40) CYP2D6CYP1A2CYP3A4CYP2C19TSHR
SCHEMBL21709477 0.82 MEN1 (0.45) CYP2D6CYP1A2CYP3A4CYP2C19TSHR
SCHEMBL17752850 0.81 KDM4E (0.32) CYP2D6CYP1A2CYP3A4CYP2C19TSHR
SCHEMBL21709397 0.80 PDE5A (0.42) CYP2D6CYP1A2CYP3A4CYP2C19TSHR
SCHEMBL21709277 0.80 CYP2D6 (0.47) CYP2D6CYP1A2CYP3A4CYP2C19TSHR
SCHEMBL17974878 0.79 PDK2 (0.37) LMNASMN1; SMN2KDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200048207-A1 COMPOUNDS WITH ARYLAMINE STRUCTURES MERCK PATENT GMBH (DE) 2020-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048207-A1 COMPOUNDS WITH ARYLAMINE STRUCTURES DDT, NAT1, INMT CYP2D6 24/4885CYP1A2 64/4885CYP3A4 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.